Archive


Category: Brian Klepper

  • THCB Gang Episode 95, Thursday June 9, 1pm PT 4pm ET

    Joining Matthew Holt (@boltyboy) on #THCBGang on Thursday June 9 at 1pm PT 4pm ET will be THCB regular writer and ponderer of odd juxtapositions Kim Bellard (@kimbbellard); fierce patient activist Casey Quinlan (@MightyCasey); & Principal of Worksite Health Advisors Brian Klepper (@bklepper1) You can see the video below live (and later archived) & if you’d rather […]

  • THCB Gang Episode 89, Thursday April 28, 1pm PT 4pm ET

    Joining Matthew Holt (@boltyboy) on #THCBGang on April 28 for an hour of topical and sometime combative conversation on what’s happening in health care are: THCB regular writer and ponderer of odd juxtapositions Kim Bellard (@kimbbellard); medical historian Mike Magee (@drmikemagee); patient safety expert and all around wit Michael Millenson (@mlmillenson) & Principal of Worksite Health Advisors […]

  • THCB Gang Episode 85, Thursday March 17th, 1pm PT 4pm ET

    Joining Matthew Holt (@boltyboy) on #THCBGang at 1pm PT 4pm ET Thursday for an hour of topical and sometime combative conversation on what’s happening in health care and beyond will be: double trouble futurists Ian Morrison (@seccurve) & Jeff Goldsmith; consultant focusing on platform business models and strategy Vince Kuraitis (@VinceKuraitis), & back after a long […]

  • Where Health Care Value Can Lead

    By BRIAN KLEPPER It seems inevitable that, in the near future, an innovative health care organization – Let’s call it The Platform – is going to seize the market opportunity of broader value. It will cobble together the pieces, and demonstrate to organizational purchasers that it consistently delivers better health outcomes at significantly lower cost […]

  • Tying Health Care Investment to Performance

    By BRIAN KLEPPER and JEFFREY HOGAN GoodRx’s planned initial public offering recently made the news, notable because the company, launched in 2011, has been profitable since 2016. Evidently, it’s become unfashionable for investors to demand proof of performance, so GoodRx’s results shone like a beacon. By contrast, most health care firms seeking funding convey bold […]